Valuation: Silence Therapeutics plc

Market Cap 358M 479M 420M 387M 680M 45.5B 691M 4.64B 1.8B 22.46B 1.8B 1.76B 77.62B P/E 2026 *
-17x
P/E 2027 * -15.1x
Enterprise Value 212M 284M 248M 229M 402M 26.91B 409M 2.74B 1.07B 13.28B 1.06B 1.04B 45.9B EV / Sales 2026 *
84.9x
EV / Sales 2027 * 31.7x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.06%
1 week-7.56%
Current month-7.56%
1 month+64.51%
3 months+81.25%
6 months+75.00%
Current year+66.94%
1 week 10.1
Extreme 10.1
11.06
1 month 5.88
Extreme 5.88
11.06
Current year 4.19
Extreme 4.19
11.06
1 year 4.19
Extreme 4.19
11.06
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 14/12/2025
Director of Finance/CFO 54 21/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/12/2019
Director/Board Member 54 18/12/2025
Date Insider Type Main position Quantity % Market Cap.
01-02Free

Director

90,000 0.0635%
01-02Free

Director

90,000 0.0635%
01-02Free

Chief Technology Officer

300,000 0.2117%
Change 5-day change 1-year change 3-year change Capi.($)
-4.06%-7.56%+77.14%+77.14% 479M
-1.03%+5.24%+2.94%+9.41% 49.74B
+0.25%+1.70%+419.39%+621.71% 40.49B
-0.16%+8.42%+28.20%+63.00% 34.35B
+1.10%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
-0.35%+0.09% - - 16.58B
-3.33%+3.15%+71.30%+131.94% 15.6B
+3.79%+8.88%+106.63%+106.63% 14.27B
+0.32%+0.53%+14.33%+21.47% 13.76B
Average -0.22%+3.03%+83.69%+117.91% 24.7B
Weighted average by Cap. +0.10%+4.56%+95.83%+141.02%

Financials

2026 *2027 *
Net sales 2.5M 3.34M 2.92M 2.69M 4.74M 317M 4.81M 32.28M 12.55M 156M 12.53M 12.26M 540M 3.44M 4.6M 4.03M 3.71M 6.53M 437M 6.64M 44.51M 17.31M 216M 17.28M 16.91M 745M
Net income -50.34M -67.34M -58.93M -54.31M -95.56M -6.39B -97.1M -651M -253M -3.15B -253M -247M -10.9B -84.67M -113M -99.12M -91.35M -161M -10.75B -163M -1.1B -426M -5.31B -425M -416M -18.34B
Net Debt -146M -196M -171M -158M -278M -18.59B -282M -1.89B -737M -9.18B -735M -720M -31.72B -249M -334M -292M -269M -473M -31.67B -481M -3.23B -1.25B -15.63B -1.25B -1.23B -54.02B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
07/07/26 $10.15 -4.06% 617,739
06/07/26 $10.58 +1.83% 578,918
02/07/26 $10.39 -1.05% 696,727
01/07/26 $10.50 -4.37% 718,986
30/06/26 $10.98 +1.76% 556,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.15USD
Average target price
29.17USD
Spread / Average Target
+187.36%

Quarterly revenue - Rate of surprise